Lei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Zhang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Wenhui Lou
Department of Pancreatic Surgery, ZhongShan Hospital, Fudan University, Shanghai, China
6 shared publicationsJiale Feng
Department of Pancreatic Surgery Zhongshan Hospital Fudan University Shanghai China
4 shared publications- Liang Liu
Department of Pancreatic Surgery, ZhongShan Hospital, Fudan University, Shanghai, China
4 shared publications Dansong Wang
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
3 shared publicationsDayong Jin
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
3 shared publicationsJianang Li
Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (11)
Selective AUTAC‐mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma
Cuproptosis arises from mitochondrial copper overload, yet how tumour cells evade this metabolic vulnerability remains unclear. We identify ATP7B as the central barrier to cuproptosis in pancreatic ductal adenocarcinoma (PDAC). ATP7B is aberrantly upregulated in PDAC and predicts poor prognosis. Its depletion increases intracellular copper, activates FDX1, DLAT/DLST lipoylation, disrupts tricarboxylic acid (TCA) metabolism, and reinstates cuproptosis in vitro and in vivo. Mechanistically, ATP7B undergoes ZBTB10‐driven K63‐linked ubiquitination, recognized by NBR1 for selective autophagic degradation. Leveraging this, we developed an ATP7B‐targeting autophagy‐targeting chimera (ATAUTAC) that promotes ATP7B clearance, amplifies copper‐driven mitochondrial metabolic perturbations, triggers cuproptosis, and inhibits tumour growth with favourable tolerability. Notably, ATAUTAC sensitizes PDAC to gemcitabine, overcoming resistance by exposing latent metabolic fragility. These findings establish ATP7B as a mechanistic hub of cuproptosis tolerance and demonstrate that autophagy‐based ATP7B degradation is a druggable strategy for copper‐dependent tumour eradication. ATAUTAC offers a promising avenue for precision therapy in PDAC and other refractory malignancies.
- 27 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (11)
Open AccessSelective AUTAC‐mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma
Cuproptosis arises from mitochondrial copper overload, yet how tumour cells evade this metabolic vulnerability remains unclear. We identify ATP7B as the central barrier to cuproptosis in pancreatic ductal adenocarcinoma (PDAC). ATP7B is aberrantly upregulated in PDAC and predicts poor prognosis. Its depletion increases intracellular copper, activates FDX1, DLAT/DLST lipoylation, disrupts tricarboxylic acid (TCA) metabolism, and reinstates cuproptosis in vitro and in vivo. Mechanistically, ATP7B undergoes ZBTB10‐driven K63‐linked ubiquitination, recognized by NBR1 for selective autophagic degradation. Leveraging this, we developed an ATP7B‐targeting autophagy‐targeting chimera (ATAUTAC) that promotes ATP7B clearance, amplifies copper‐driven mitochondrial metabolic perturbations, triggers cuproptosis, and inhibits tumour growth with favourable tolerability. Notably, ATAUTAC sensitizes PDAC to gemcitabine, overcoming resistance by exposing latent metabolic fragility. These findings establish ATP7B as a mechanistic hub of cuproptosis tolerance and demonstrate that autophagy‐based ATP7B degradation is a druggable strategy for copper‐dependent tumour eradication. ATAUTAC offers a promising avenue for precision therapy in PDAC and other refractory malignancies.
- Open Access
- 8 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8504
ASO Visual Abstract: In Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video
- 8 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8504
Open AccessASO Visual Abstract: In Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video
- Open Access
- 5 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Efficacy of LNP@2DG-DON liposomal nanoparticles in tumor inhibition and immune activation
Background: Pancreatic cancer has poor prognosis, and immunotherapy efficacy is limited by PD-L1 stability via GFAT1-mediated glycosylation. We developed LNP@2DG-DON, a liposomal nanoparticle co-delivering glycolysis inhibitor 2DG and GFAT1 inhibitor DON, to enhance antitumor immunity and metabolic targeting. Methods: LNP@2DG-DON nanoparticles were synthesized using the thin-film dispersion method and characterized for size, stability, drug loading, and release profiles. In vitro studies assessed cytotoxicity, apoptosis, migration, and invasion in ASPC-1 and PANC-1 pancreatic cancer cell lines. In vivo efficacy was evaluated in a subcutaneous xenograft mouse model, measuring tumor growth, immune cell infiltration, and survival. Western blotting, flow cytometry, and immunohistochemistry were employed to analyze molecular and cellular mechanisms. Results: LNP@2DG-DON showed uniform size (100–120 nm), high drug loading (6.84–9.27%), and sustained release. It significantly reduced cell viability, induced apoptosis, and inhibited metastasis in vitro. In vivo, it suppressed tumor growth, prolonged survival, and increased CD8+/NK cell infiltration while reducing immunosuppressive cells. Mechanistically, it downregulated PD-L1/GFAT1 and activated pro-apoptotic pathways. Conclusions: The dual-targeting LNP@2DG-DON nanoparticle synergistically combines metabolic and immune modulation, demonstrating superior antitumor effects compared to single-agent therapies. This approach represents a promising strategy for pancreatic cancer treatment, warranting further clinical investigation.
- 5 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessEfficacy of LNP@2DG-DON liposomal nanoparticles in tumor inhibition and immune activation
Background: Pancreatic cancer has poor prognosis, and immunotherapy efficacy is limited by PD-L1 stability via GFAT1-mediated glycosylation. We developed LNP@2DG-DON, a liposomal nanoparticle co-delivering glycolysis inhibitor 2DG and GFAT1 inhibitor DON, to enhance antitumor immunity and metabolic targeting. Methods: LNP@2DG-DON nanoparticles were synthesized using the thin-film dispersion method and characterized for size, stability, drug loading, and release profiles. In vitro studies assessed cytotoxicity, apoptosis, migration, and invasion in ASPC-1 and PANC-1 pancreatic cancer cell lines. In vivo efficacy was evaluated in a subcutaneous xenograft mouse model, measuring tumor growth, immune cell infiltration, and survival. Western blotting, flow cytometry, and immunohistochemistry were employed to analyze molecular and cellular mechanisms. Results: LNP@2DG-DON showed uniform size (100–120 nm), high drug loading (6.84–9.27%), and sustained release. It significantly reduced cell viability, induced apoptosis, and inhibited metastasis in vitro. In vivo, it suppressed tumor growth, prolonged survival, and increased CD8+/NK cell infiltration while reducing immunosuppressive cells. Mechanistically, it downregulated PD-L1/GFAT1 and activated pro-apoptotic pathways. Conclusions: The dual-targeting LNP@2DG-DON nanoparticle synergistically combines metabolic and immune modulation, demonstrating superior antitumor effects compared to single-agent therapies. This approach represents a promising strategy for pancreatic cancer treatment, warranting further clinical investigation.
- Open Access
- 23 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5100-5101
In Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video
Background: Dissection around the superior mesenteric artery (SMA) is a crucial and one of the most challenging processes in laparoscopic pancreaticoduodenectomy (LPD) owing to the deep anatomic location and the indispensable role of SMA. Multiple approaches to SMA during LPD have been proposed, but most of them require the transection of the jejunum or the neck of pancreas in advance and may cause significant tension on mesenteric vessels that may lead to accidental bleeding. 1–3 Here, we describe an in situ anterior approach to the SMA that aids in the early assessment of tumor resectability without any destructive steps and minimizes bleeding risk. Patients and Methods: An 85-year-old man underwent LPD for a distal common bile duct carcinoma, with a percutaneous transhepatic biliary drainage (PTBD) placed 4 weeks prior. Preoperative imaging showed a rare first jejunal vein that runs in front of the SMA and drains into the junction of the SMV and the spleen vein. The in situ anterior approach to the SMA begins with the identification of superior mesenteric vein (SMV) at the inferior border of the pancreas. The right gastroepiploic vein, and right colic vein and gastrocolic trunk are clipped and divided. The SMV is exposed to the level of third portion of the duodenum. Then the left side of the SMV or the “groove” between SMV and SMA is dissected. The colic vein draining into the SMV is clipped and divided. The first jejunal vein that drains into the junction of the SMV and the spleen vein is also clipped and divided. With the surgeon and the assistant grasping the fibrofatty tissue in the “groove” and pulling ventrally in opposite positions, the fibrofatty tissue and neural plexus around the SMA are dissected. In this way the SMA can be skeletonized in a ventral-to-dorsal direction. During the process, the IPDA, the first jejunal artery and their common trunk are identified. The distal end of J1A and the common trunk of IPDA and J1A are securely clipped and divided. The posterior dissection ends when the inferior vena cava or the gauze placed behind the duodenum during the Kocher maneuver is revealed. The dissection could continue cephalad to remove the lymph nodes in the Heidelberg Triangle. 4 The dorsal pancreatic artery is clipped and divided. Results: In this case, the operative time was 340 min with an estimated blood loss of 200 ml. The patient recovered uneventfully with no pancreatic fistula and was discharged on postoperative day 8. Histology confirmed poorly-differentiated biliary adenocarcinoma with no involvement of the lymph nodes. Conclusions: The video illustrates an in situ anterior approach to dissect the superior mesenteric artery in laparoscopic pancreaticoduodenectomy that largely resembles the supracolic anterior artery-first approach in open surgery proposed by Inoue et al. 5 This approach reduces the risk of vascular injury and bleeding by omitting the significant tension on mesenteric vessels as organs stay in their original positions, and the nondestructive and “reversable” nature makes it easier to achieve an accurate evaluation of tumor resectability early in the surgery.
- 23 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5100-5101
Open AccessIn Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video
Background: Dissection around the superior mesenteric artery (SMA) is a crucial and one of the most challenging processes in laparoscopic pancreaticoduodenectomy (LPD) owing to the deep anatomic location and the indispensable role of SMA. Multiple approaches to SMA during LPD have been proposed, but most of them require the transection of the jejunum or the neck of pancreas in advance and may cause significant tension on mesenteric vessels that may lead to accidental bleeding. 1–3 Here, we describe an in situ anterior approach to the SMA that aids in the early assessment of tumor resectability without any destructive steps and minimizes bleeding risk. Patients and Methods: An 85-year-old man underwent LPD for a distal common bile duct carcinoma, with a percutaneous transhepatic biliary drainage (PTBD) placed 4 weeks prior. Preoperative imaging showed a rare first jejunal vein that runs in front of the SMA and drains into the junction of the SMV and the spleen vein. The in situ anterior approach to the SMA begins with the identification of superior mesenteric vein (SMV) at the inferior border of the pancreas. The right gastroepiploic vein, and right colic vein and gastrocolic trunk are clipped and divided. The SMV is exposed to the level of third portion of the duodenum. Then the left side of the SMV or the “groove” between SMV and SMA is dissected. The colic vein draining into the SMV is clipped and divided. The first jejunal vein that drains into the junction of the SMV and the spleen vein is also clipped and divided. With the surgeon and the assistant grasping the fibrofatty tissue in the “groove” and pulling ventrally in opposite positions, the fibrofatty tissue and neural plexus around the SMA are dissected. In this way the SMA can be skeletonized in a ventral-to-dorsal direction. During the process, the IPDA, the first jejunal artery and their common trunk are identified. The distal end of J1A and the common trunk of IPDA and J1A are securely clipped and divided. The posterior dissection ends when the inferior vena cava or the gauze placed behind the duodenum during the Kocher maneuver is revealed. The dissection could continue cephalad to remove the lymph nodes in the Heidelberg Triangle. 4 The dorsal pancreatic artery is clipped and divided. Results: In this case, the operative time was 340 min with an estimated blood loss of 200 ml. The patient recovered uneventfully with no pancreatic fistula and was discharged on postoperative day 8. Histology confirmed poorly-differentiated biliary adenocarcinoma with no involvement of the lymph nodes. Conclusions: The video illustrates an in situ anterior approach to dissect the superior mesenteric artery in laparoscopic pancreaticoduodenectomy that largely resembles the supracolic anterior artery-first approach in open surgery proposed by Inoue et al. 5 This approach reduces the risk of vascular injury and bleeding by omitting the significant tension on mesenteric vessels as organs stay in their original positions, and the nondestructive and “reversable” nature makes it easier to achieve an accurate evaluation of tumor resectability early in the surgery.
- Open Access
- 10 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4536-4542
Crystal-storing histiocytosis associated with MALT Lymphoma: a case report and literature review
Introduction and importance: Crystal-storing histiocytosis (CSH) is a rare, non-neoplastic histiocytic proliferation that often complicates underlying lymphoproliferative or plasma cell disorders. The respiratory system is uncommonly involved in CSH. We present a local case of pulmonary CSH associated with marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), along with eight additional cases identified from a literature review. Case presentation: A 64-year-old woman was admitted to the hospital for coughing, expectoration, and asthma for more than 1 year. Chest CT revealed localized thickening of the tracheal wall, and the bronchoscopy examination showed neoplasms of the trachea and bronchus mucosa. The lesion was characterized by sheets of histiocytes with abundant eosinophilic cytoplasm and scattered aggregates of atypical lymphoid cells. Immunohistochemical stains and T/B-cell gene rearrangement studies supported the pathological diagnosis of CSH-associated MALT. The patient remained free from the disease after lesion resection via bronchoscopy, with further treatment of targeted therapy. Clinical discussion: Pulmonary CSH-associated MALT can occur in patients of various ages and genders with non-specific clinical and imaging features. Histopathological examination is essential for differentiating CSH from similar conditions. The pathogenesis of CSH may relate to the overproduction of immunoglobulins, and the immunoglobulin types involved in the cases we described are predominantly kappa light chains. Conclusion: Recognizing CSH is essential for starting a clinical evaluation to identify the underlying neoplasm or associated causes. A conclusive diagnosis relies on pathological examination. More detailed case reports are needed to clarify pathogenesis and improve diagnosis, treatment strategies, and patient outcomes.
- 10 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4536-4542
Open AccessCrystal-storing histiocytosis associated with MALT Lymphoma: a case report and literature review
Introduction and importance: Crystal-storing histiocytosis (CSH) is a rare, non-neoplastic histiocytic proliferation that often complicates underlying lymphoproliferative or plasma cell disorders. The respiratory system is uncommonly involved in CSH. We present a local case of pulmonary CSH associated with marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), along with eight additional cases identified from a literature review. Case presentation: A 64-year-old woman was admitted to the hospital for coughing, expectoration, and asthma for more than 1 year. Chest CT revealed localized thickening of the tracheal wall, and the bronchoscopy examination showed neoplasms of the trachea and bronchus mucosa. The lesion was characterized by sheets of histiocytes with abundant eosinophilic cytoplasm and scattered aggregates of atypical lymphoid cells. Immunohistochemical stains and T/B-cell gene rearrangement studies supported the pathological diagnosis of CSH-associated MALT. The patient remained free from the disease after lesion resection via bronchoscopy, with further treatment of targeted therapy. Clinical discussion: Pulmonary CSH-associated MALT can occur in patients of various ages and genders with non-specific clinical and imaging features. Histopathological examination is essential for differentiating CSH from similar conditions. The pathogenesis of CSH may relate to the overproduction of immunoglobulins, and the immunoglobulin types involved in the cases we described are predominantly kappa light chains. Conclusion: Recognizing CSH is essential for starting a clinical evaluation to identify the underlying neoplasm or associated causes. A conclusive diagnosis relies on pathological examination. More detailed case reports are needed to clarify pathogenesis and improve diagnosis, treatment strategies, and patient outcomes.
- Open Access
Unveiling Circulating Targets in Pancreatic Cancer: Insights from Proteogenomic Evidence and Clinical Cohorts
Pancreatic cancer (PC), lacking biomarkers and effective therapeutics, remains highly lethal. Data regarding the correlations of PC risk and the individual plasma proteome known for minimally cancer biomarkers, are scarce. Here, we measure 1,345 human plasma proteins via Proteome-Wide Association Studies, presenting 78 proteins are prominently related to PC risk, including 4 proteins (ROR1, FN1, APOA5, ABO) exhibit the strongest causal association identified via Mendelian Randomization and Colocalization. Our two independent cohorts further demonstrate FN1 and ABO are highly expressed in blood or tumors from patients with PC compared to specimens from healthy individuals or para-tumors. Moreover, patients with higher levels of FN1 and ABO in their blood or tumors have worse median survival than those with lower levels. Multiple drugs targeting FN1 are currently available or undergoing clinical testing, making FN1 a promisingly repurposed therapeutic target in addition to severing as a circulating prognostic indicator for PC.
Open AccessUnveiling Circulating Targets in Pancreatic Cancer: Insights from Proteogenomic Evidence and Clinical Cohorts
Pancreatic cancer (PC), lacking biomarkers and effective therapeutics, remains highly lethal. Data regarding the correlations of PC risk and the individual plasma proteome known for minimally cancer biomarkers, are scarce. Here, we measure 1,345 human plasma proteins via Proteome-Wide Association Studies, presenting 78 proteins are prominently related to PC risk, including 4 proteins (ROR1, FN1, APOA5, ABO) exhibit the strongest causal association identified via Mendelian Randomization and Colocalization. Our two independent cohorts further demonstrate FN1 and ABO are highly expressed in blood or tumors from patients with PC compared to specimens from healthy individuals or para-tumors. Moreover, patients with higher levels of FN1 and ABO in their blood or tumors have worse median survival than those with lower levels. Multiple drugs targeting FN1 are currently available or undergoing clinical testing, making FN1 a promisingly repurposed therapeutic target in addition to severing as a circulating prognostic indicator for PC.
- Open Access
The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy
The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec–sialic acid interaction as a novel cancer therapeutic strategy.
Open AccessThe Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy
The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec–sialic acid interaction as a novel cancer therapeutic strategy.
- Open Access
- 1 May 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (10) , 544
GFAT1 is highly expressed in cancer stem cells of pancreatic cancer
Original Article GFAT1 is highly expressed in cancer stem cells of pancreatic cancer Zhe Wang, Tiantao Kuang, Wenchuan Wu, Dansong Wang, Wenhui Lou, Dayong Jin, Xuefeng Xu, Lei Zhang
- 1 May 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (10) , 544
Open AccessGFAT1 is highly expressed in cancer stem cells of pancreatic cancer
Original Article GFAT1 is highly expressed in cancer stem cells of pancreatic cancer Zhe Wang, Tiantao Kuang, Wenchuan Wu, Dansong Wang, Wenhui Lou, Dayong Jin, Xuefeng Xu, Lei Zhang
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (5) , 1501-1511
PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor with an extremely poor prognosis in digestive tumors. Pyrroline-5-carboxylate reductase 1 (PYCR1) plays an important role in tumor development. Therefore, we aimed to explore the effect of PYCR1 on the growth of PDAC cells.
- 1 January 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (5) , 1501-1511
Open AccessPYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor with an extremely poor prognosis in digestive tumors. Pyrroline-5-carboxylate reductase 1 (PYCR1) plays an important role in tumor development. Therefore, we aimed to explore the effect of PYCR1 on the growth of PDAC cells.